BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Metrics to compare | BLRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBLRXPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.6x | −2.1x | −0.5x | |
PEG Ratio | −0.06 | −0.03 | 0.00 | |
Price/Book | 0.9x | 2.7x | 2.6x | |
Price / LTM Sales | 0.9x | 9.3x | 3.2x | |
Upside (Analyst Target) | - | 423.6% | 40.5% | |
Fair Value Upside | Unlock | 4.1% | 4.4% | Unlock |